Clinical Trial: OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE II STUDY OF AROXXEN(R) INHALATION FOR CARDIOPROTECTION AFTER ELECTIVE PCI WITH STENT IMPLANTATION

U.S., Feb. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07397351) titled 'OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE II STUDY OF AROXXEN(R) INHALATION FOR CARDIOPROTECTION AFTER ELECTIVE PCI WITH STENT IMPLANTATION' on Feb. 02.

Brief Summary: This is an open-label, randomized, multicenter Phase II clinical study designed to evaluate the cardioprotective effect, to determine the optimal dosages and duration of inhalation, and to assess the clinical safety of the medicinal product Aroxxen(R) in patients undergoing elective percutaneous coronary intervention (PCI) with stent implantation.

Patients who undergo elective PCI are at risk of myocardial injury associated with the procedure. The study aims to asses...